AZD9592 + Rilvegostomig

COMBINATION_PRODUCT2 trials

Sponsors

Presage Biosciences

Conditions

Head and Neck Squamous Cell CarcinomaSolid Tumor

Early Phase 1

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Active, not recruitingNCT04541108

Presage BiosciencesSolid Tumor

Start: 2021-07-26End: 2031-12-01Target: 15Updated: 2026-05-22

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

CompletedNCT06366451

Presage BiosciencesHead and Neck Squamous Cell Carcinoma

Start: 2024-05-22End: 2026-03-25Updated: 2026-06-26

Related Papers

722 Evaluation of the effects of pembrolizumab alone and in combination(s) with MDSC-targeting agents MK-0482 and MK-4830 on the native cancer patient TME via functional spatial profiling (CIVO®)

Regular and Young Investigator Award Abstracts2023-10-311 citations

Multiplexed trackable intratumor microdosing of the investigational STING agonist TAK-676 alone and in combination in the native tumor microenvironment of patients with head and neck cancer: A phase 0 trial.

Journal of Clinical Oncology2023-06-013 citations

Abstract 620: Intratumoral microdosing via the CIVO® Platform reveals anti-tumor immune responses induced by the STING Agonist TAK-676 alone and in combination with chemotherapies

Cancer Research2022-06-151 citations

Abstract CT216: A phase 0 master protocol utilizing a novel intratumoral microdosing approach for simultaneously evaluating multiple drugs and drug combinations in patients with solid tumors

Cancer Research2022-06-15